Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2008.

Vanda reported research and development (R&D) expenses in the third quarter of 2008 of $3.8 million, compared to $5.5 million in the second quarter of 2008 and $13.9 million in the third quarter of 2007. The decrease in R&D expenses in the third quarter of 2008 relative to the second quarter of 2008 is primarily attributable to lower costs in the Phase III tasimelteon (VEC-162) chronic primary insomnia clinical trial for which Vanda announced top-line results in June of 2008. The decrease in R&D expenses in the third quarter of 2008 relative to the third quarter of 2007 is attributable to lower clinical trial costs in 2008 compared to costs from trials conducted in 2007, and the $5.0 million milestone charge recorded in the third quarter of 2007 resulting from the submission of the New Drug Application (NDA) for iloperidone.

Net loss was $10.9 million for the third quarter of 2008, compared to $13.5 million for the second quarter of 2008 and $21.9 million for the third quarter of 2007. Net loss per common share for the third quarter of 2008 was $0.41, compared to $0.51 for the second quarter of 2008 and $0.82 for the third quarter of 2007.

As of September 30, 2008, Vanda's cash, cash equivalents, and marketable securities totaled approximately $51.7 million. As of September 30, 2008, Vanda had a total of approximately 26.7 million shares of common stock outstanding.

OPERATIO
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... 10, 2014 Terascala, the industry leader ... Alan Swahn, a former vice president of product management ... vice president of marketing. Terascala’s software when combined with ... create the highest performance and most reliable solutions for ... guide Terascala’s channel expansion and broaden its product portfolio. ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... for an interview with a researcher, please contact the Communications ... each tip. For more information on ORNL and its research ... Contacts. If you have a general media-related question or comment, ... MATERIALS Moving toward nanorobots . . . ...
... Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced ... (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety ... of Adenovirus Disease Following H em ... T ransplantation [HSCT]).The company also announced that the ...
... Mass., July 12, 2011 Comprendia, leading developer ... the life sciences, sponsored by molecular biology reagents ... an online resource that will support epigenetics research. ... implications for oncology, neurology, metabolism and disease mechanisms. ...
Cached Biology Technology:Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 3Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 4Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 2Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 3Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 4Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 5Comprendia and New England Biolabs Connect Epigenetics Scientists with New Social Media Application 2Comprendia and New England Biolabs Connect Epigenetics Scientists with New Social Media Application 3
(Date:7/10/2014)... -- Fingerprint Cards, (FPC,s) new mobile touch sensor ... Chinese Top 5 smartphone OEM has selected FPC1021 for a ... October 2014.   FPC is proud to announce ... has a planned date for the start of mass production ... phone of 3 million units. The Chinese OEM wants to ...
(Date:7/10/2014)... Sweden , July 8, 2014 ... has won a new design win (DW). An Asian OEM ... date for mass production start in August 2014.   ... Asian smartphone OEM, which has a planned date for start ... an initial ramp order of SEK 5M, for delivery in ...
(Date:7/10/2014)... Ill. , July 9, 2014 ... (EHR), spurred in large part by meaningful use ... health care providers interact with laboratory information. Now, ... in the field of clinical informatics in order ... To address the educational needs of ...
Breaking Biology News(10 mins):FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4
... led by Northwestern Medicine scientists has identified how a defective ... disease known as Giant Axonal Neuropathy, or GAN. The finding ... Investigation . GAN is an extremely rare and ... systems of young children. Those affected show no symptoms at ...
... Health today announced that Vetsulin (porcine insulin zinc suspension), the ... is now available to veterinarians throughout the United States. ... from one in 1001 to one in 500, 2 and ... during the past 30 years.3 Today, along with proper diet ...
... cat, it instinctively avoids the feline or risks becoming dinner. ... the sense of smell, provides evidence that a single gene ... by neurobiologist Thomas Bozza has shown that removing one olfactory ... behavior. The gene, called TAAR4, encodes a receptor that responds ...
Cached Biology News:Rare, lethal childhood disease tracked to protein 2Merck Animal Health announces Vetsulin 2Cat and mouse: A single gene matters 2Cat and mouse: A single gene matters 3
...
... The 500 optimization kit is for fine-tuning ... interest. The kit is recommended when you ... system. The kit includes 0.25 g each ... micrometer diameter gold microcarriers, 100 each of ...
... specifically designed for two-dimensional electrophoresis (2D) ... proteins in this marker have been ... across a 2D gel. The pI ... Mol wt: 17,000-89,000 Physical ...
... can be used to test the crossreactivity ... sera that are commonly used as blocking ... spots for 21 different protein preparations on ... crossreactivity and species specificity, QC of purified ...
Biology Products: